Midostaurin (PKC412) is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is a semi-synthetic derivative of staurosporine an alkaloid from the bacterium Streptomyces staurosporeus and is active in patients with mutations of CD135 (FMS-like tyrosine kinase 3 receptor).After successful Phase II clinical trials a Phase III trial for AML has started in 2008.
This page contains content from the copyrighted Wikipedia article "Midostaurin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
